Natera Stock Analysis: Why This Cancer Testing Stock Could Triple
Let’s start with something remarkable. Natera (NASDAQ: NTRA) just celebrated its 10th anniversary as a public company, and what a journey it’s been. The stock has delivered nearly 10x returns, climbing from its $18 IPO price to around $170 today. But here’s what makes this even more impressive – revenues have grown equally, expanding 10-fold from $190 million to $2 billion. This is good, but there is something more. Last twelve months revenue growth was a stellar 44%.
But what’s driving this growth? It all comes down to one word: intelligence. Medical intelligence, to be precise. Natera has positioned itself at the cutting edge of molecular diagnostics, particularly for cancer detection and monitoring. Think of them as…
